Several new autoimmune drugs targeting previously untapped biological pathways have reached approval or late-stage development, and they represent the most significant shift in autoimmune treatment strategy in years. Among the most notable is ianalumab, a Novartis monoclonal antibody that targets the BAFF receptor — a pathway never before addressed by any approved autoimmune therapy — which received FDA Breakthrough Therapy Designation in January 2026 for Sjögren’s disease. Meanwhile, Kyverna Therapeutics is on track to submit the first-ever CAR-T cell therapy for an autoimmune condition, and two BTK inhibitors originally developed in oncology have already crossed over into autoimmune approvals.
For anyone following brain health and dementia care, this wave matters more than it might first appear. Autoimmune conditions like Sjögren’s disease and lupus can drive neuroinflammation, cognitive fog, and in some cases accelerate neurodegenerative processes. The emergence of drugs that work through entirely new mechanisms — rather than the same recycled immunosuppressants — opens real questions about whether controlling autoimmune disease earlier and more precisely could protect the brain down the line. This article breaks down each of these novel therapies, what makes their mechanisms genuinely new, and what the practical implications are for patients and caregivers.
Table of Contents
- What New Autoimmune Drugs Target Never-Before-Seen Pathways, and Why Does It Matter?
- How Ianalumab Could Change the Landscape for Sjögren’s Disease and Neuroinflammation
- CAR-T Therapy for Autoimmune Disease — A Cancer Treatment Finds a Second Life
- BTK Inhibitors Cross Over From Cancer — What Patients Should Know About Rilzabrutinib and Remibrutinib
- The Neuroinflammation Connection — Why Autoimmune Breakthroughs Matter for Brain Health
- Rocatinlimab and the OX40 Pathway — Another Novel Target on the Horizon
- What the 2025–2026 Approval Wave Signals for the Future of Autoimmune and Brain Health Treatment
- Conclusion
- Frequently Asked Questions
What New Autoimmune Drugs Target Never-Before-Seen Pathways, and Why Does It Matter?
The phrase “never-before-seen pathway” gets thrown around loosely in pharmaceutical marketing, but in this case, it is largely accurate for at least two therapies. Ianalumab is a fully human monoclonal antibody with a dual mechanism of action: it depletes B cells while simultaneously blocking their activation and survival by targeting the BAFF receptor. No previously approved autoimmune drug has gone after this specific receptor. If it clears regulatory review, ianalumab would also be the first targeted treatment ever approved for Sjögren’s disease — the second most prevalent rheumatic autoimmune condition, which until now has been managed with symptom-level interventions rather than disease-modifying therapy.
The second genuinely novel approach comes from Kyverna’s miv-cel (KYV-101), an anti-CD19 CAR-T cell therapy repurposed from cancer treatment. CAR-T works by engineering a patient’s own T cells to hunt down and eliminate autoreactive B cells, essentially resetting the immune system. This technology has been used in blood cancers for several years, but applying it to autoimmune disease is an entirely different proposition. Kyverna is on track to submit a Biologics License Application in the first half of 2026 for Stiff Person Syndrome, which would make it the first CAR-T therapy ever approved for an autoimmune indication. The contrast between these two approaches is instructive: ianalumab modulates a specific receptor to interrupt B cell survival signaling, while miv-cel goes after the B cells themselves with a search-and-destroy strategy borrowed from oncology.
How Ianalumab Could Change the Landscape for Sjögren’s Disease and Neuroinflammation
Sjögren’s disease affects an estimated four million Americans, causing dry eyes, dry mouth, joint pain, and fatigue. But what gets less attention is its neurological toll. Up to 20 percent of Sjögren’s patients experience peripheral neuropathy, and many report persistent cognitive dysfunction — sometimes called “brain fog” — that can mimic early dementia symptoms. Without a disease-modifying treatment, clinicians have been limited to managing these symptoms with artificial tears, saliva substitutes, and broad immunosuppressants that carry their own cognitive side effects.
Ianalumab’s positive results from two replicate Phase III trials — NEPTUNUS-1 and NEPTUNUS-2, reported in August 2025 — showed that the drug met primary endpoints on disease activity with a safety profile comparable to placebo. Novartis plans to submit for regulatory approval globally starting in early 2026. However, it is important to temper expectations: meeting disease activity endpoints in a clinical trial does not automatically mean the drug will reverse established neurological damage from Sjögren’s. If the disease has already caused nerve injury or sustained neuroinflammation, a drug that controls B cell activity going forward may prevent further decline without restoring what has been lost. Patients and caregivers should understand that earlier intervention — catching the autoimmune process before it damages the nervous system — is likely where this drug would offer the most neurological benefit.
CAR-T Therapy for Autoimmune Disease — A Cancer Treatment Finds a Second Life
The idea of using CAR-T therapy outside of cancer seemed speculative just a few years ago, but Kyverna’s Phase 2 registrational trial for Stiff Person Syndrome (KYSA-8) has produced results that are difficult to dismiss. The trial showed highly statistically significant results on primary and all secondary endpoints, with participants demonstrating a median 46 percent improvement on a timed walking test at four months post-treatment. For a condition as debilitating as Stiff Person Syndrome — a rare neurological autoimmune disorder that causes progressive muscle stiffness and spasms — that degree of functional improvement is striking.
Kyverna is also running Phase 1/2 trials for lupus nephritis (the KYSA-1 and KYSA-3 studies), with sustained efficacy reported at six-month follow-up. Lupus is another autoimmune condition with significant neuropsychiatric overlap: neuropsychiatric lupus can cause seizures, psychosis, and cognitive impairment. The prospect of a therapy that can effectively reset the immune system’s misdirected attack raises a tantalizing question for dementia care — could immune system resets slow or prevent the neuroinflammatory cascades that contribute to cognitive decline in autoimmune patients? That remains speculative, but the mechanism is biologically plausible, and it is the kind of question that researchers are beginning to take seriously.
BTK Inhibitors Cross Over From Cancer — What Patients Should Know About Rilzabrutinib and Remibrutinib
Two BTK (Bruton’s tyrosine kinase) inhibitors made history in rapid succession in 2025. Rilzabrutinib, marketed as Wayrilz by Sanofi, received FDA approval on August 29, 2025, for persistent and chronic immune thrombocytopenia, making it the first BTK inhibitor ever approved for a non-oncology indication. It works through a dual mechanism: decreasing macrophage-mediated platelet destruction while also reducing pathogenic autoantibody production. Just a month later, on September 30, 2025, Novartis’ remibrutinib (Rhapsido) was approved for chronic spontaneous urticaria — chronic hives that persist despite antihistamine treatment — becoming the second BTK inhibitor approved for a non-cancer autoimmune use. The tradeoff patients should understand is that BTK inhibitors were originally designed for blood cancers, where the tolerance for side effects is higher because the alternative is worse.
Repurposing them for autoimmune conditions means the risk-benefit calculus changes significantly. Patients with chronic hives or ITP are not facing terminal illness, so the safety bar is higher. Both rilzabrutinib and remibrutinib demonstrated acceptable safety profiles in their respective trials, but long-term data in autoimmune populations is still limited. Rilzabrutinib has since been granted Breakthrough Therapy designation for warm autoimmune hemolytic anemia, suggesting its use may expand further. For dementia caregivers managing a loved one who also has an autoimmune condition, the availability of more targeted therapies with potentially fewer cognitive side effects than traditional immunosuppressants is a practical benefit worth discussing with their medical team.
The Neuroinflammation Connection — Why Autoimmune Breakthroughs Matter for Brain Health
The relationship between autoimmune disease and dementia risk is not hypothetical. Chronic systemic inflammation — the hallmark of autoimmune conditions — is increasingly recognized as a contributor to neurodegenerative processes. Studies have linked rheumatoid arthritis, lupus, and Sjögren’s disease to elevated risks of cognitive impairment and dementia. The blood-brain barrier, once thought to be an impenetrable wall, is now understood to be permeable to inflammatory signals, meaning that peripheral autoimmune activity can drive brain inflammation even when the autoimmune disease itself does not directly target the nervous system.
However, a critical limitation must be acknowledged: none of these newly approved or pipeline drugs have been studied specifically for neuroprotection or dementia prevention. Their clinical trials measured autoimmune disease activity, not cognitive outcomes. It would be irresponsible to suggest that taking ianalumab or rilzabrutinib will prevent Alzheimer’s disease. What can be said is that better control of autoimmune inflammation — with drugs that are more targeted and potentially carry fewer cognitive side effects than older immunosuppressants like cyclophosphamide or high-dose corticosteroids — could theoretically reduce one contributing factor to neurodegeneration. Patients and caregivers should be wary of anyone overselling this connection, but they should also feel justified in asking their rheumatologist or neurologist how autoimmune disease management fits into a broader brain health strategy.
Rocatinlimab and the OX40 Pathway — Another Novel Target on the Horizon
Beyond the drugs already approved or nearing approval, rocatinlimab represents yet another genuinely novel mechanism. It targets the OX40 costimulatory signal, which sustains pathogenic T-cell responses through a pathway entirely distinct from existing biologics that block IL-4 or IL-13. Currently in late-stage development for atopic dermatitis and expected to be evaluated for approval in 2026, rocatinlimab illustrates a broader trend: drug developers are no longer content to target the same handful of inflammatory pathways.
They are mapping the immune system’s signaling architecture with increasing precision and going after nodes that were previously considered undruggable or irrelevant. For the brain health community, this matters because T-cell activity is not limited to the skin or joints. T cells cross the blood-brain barrier, and their role in neuroinflammation and even in clearing amyloid plaques is an active area of research. A drug that modulates T-cell persistence through a novel pathway may eventually have implications well beyond dermatology, though that remains years away from clinical validation.
What the 2025–2026 Approval Wave Signals for the Future of Autoimmune and Brain Health Treatment
The concentration of novel-mechanism approvals in 2025 and 2026 is not a coincidence. It reflects a decade of investment in understanding the immune system at a molecular level, combined with the realization that drugs developed for oncology — CAR-T therapies, BTK inhibitors — could be repurposed for the much larger autoimmune disease population. The pipeline beyond these approvals is substantial: multiple CAR-T programs are advancing for lupus and other systemic autoimmune diseases, additional BTK inhibitors are in development, and entirely new targets like BAFF-R and OX40 are being validated.
For dementia care, the most meaningful long-term implication may be a shift in how autoimmune diseases are treated in older adults. If newer, more targeted therapies can replace broad immunosuppressants that carry cognitive side effects — corticosteroid-induced delirium, methotrexate-related fatigue, cyclophosphamide-associated encephalopathy — that alone would be a meaningful improvement in quality of life for patients managing both autoimmune disease and cognitive vulnerability. The convergence of autoimmune and neuroscience research is still in its early chapters, but the drugs reaching the market now are the foundation that future brain-focused applications will be built on.
Conclusion
The autoimmune treatment landscape has changed more in the past year than in the previous decade. Ianalumab’s targeting of the BAFF receptor in Sjögren’s disease, miv-cel’s application of CAR-T technology to Stiff Person Syndrome, and the crossover of BTK inhibitors like rilzabrutinib and remibrutinib from oncology to autoimmune conditions each represent a genuinely new approach — not incremental improvements on existing mechanisms. For patients living with autoimmune diseases that also carry neurological consequences, these drugs offer the possibility of more precise immune control with potentially fewer collateral effects on cognition.
Caregivers and patients should bring these developments up with their treatment teams, particularly if current autoimmune medications are contributing to fatigue, confusion, or cognitive complaints. Not every new drug will be appropriate for every patient, and long-term safety data in autoimmune populations is still accumulating. But the direction is clear: the era of treating autoimmune disease with blunt-force immunosuppression is giving way to something more surgical, and the brain may ultimately be one of the biggest beneficiaries.
Frequently Asked Questions
What is ianalumab and why is it considered a breakthrough for Sjögren’s disease?
Ianalumab is a monoclonal antibody developed by Novartis that targets the BAFF receptor, a pathway never before addressed by an approved autoimmune drug. It received FDA Breakthrough Therapy Designation in January 2026 for Sjögren’s disease and, if approved, would be the first targeted treatment for the condition. Positive Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials showed it met primary endpoints on disease activity with safety comparable to placebo.
Can CAR-T therapy really be used for autoimmune diseases, not just cancer?
Yes. Kyverna Therapeutics’ miv-cel (KYV-101) is an anti-CD19 CAR-T therapy heading toward the first autoimmune approval. Its Phase 2 trial in Stiff Person Syndrome showed a median 46 percent improvement on a timed walking test at four months. The company plans to submit a Biologics License Application in the first half of 2026 and is also studying the therapy in lupus nephritis.
Do these new autoimmune drugs help with dementia or cognitive decline?
None of these drugs have been specifically studied for cognitive outcomes or dementia prevention. However, they offer more targeted immune control with potentially fewer cognitive side effects than older immunosuppressants like corticosteroids or cyclophosphamide. Better management of systemic autoimmune inflammation may reduce one contributing factor to neuroinflammation, but this connection has not been proven in clinical trials.
What are BTK inhibitors and why is their autoimmune approval significant?
BTK (Bruton’s tyrosine kinase) inhibitors were originally developed for blood cancers. Rilzabrutinib (Wayrilz) became the first BTK inhibitor approved for a non-cancer use when it was cleared for immune thrombocytopenia in August 2025, followed by remibrutinib (Rhapsido) for chronic hives in September 2025. Their crossover into autoimmune treatment represents a new class of targeted therapy for conditions previously managed with less precise drugs.
Should I ask my doctor about switching to one of these new autoimmune therapies?
If you or a loved one has an autoimmune condition — especially one with neurological symptoms like brain fog, neuropathy, or cognitive changes — it is reasonable to discuss these developments with your rheumatologist or neurologist. However, availability depends on your specific diagnosis, and some of these drugs are still awaiting full approval. Your medical team can assess whether a newer, more targeted therapy might offer advantages over your current treatment.
